Is bivalirudin a biosimilar, or a generic?
Bivalirudin is not a biosimilar. It is the active ingredient in the original drug Angiomax (and later products in the same drug class/market), and it is a small-molecule drug, not a complex biologic like the products typically considered for “biosimilar” status. Biosimilars are approved as highly similar versions of existing biologics, which are usually large, complex molecules produced in living systems.
What category does bivalirudin fall into?
Bivalirudin is an anticoagulant medication (a direct thrombin inhibitor). Because it is not classified and regulated as a biologic, it is generally discussed in terms of drug product/brand and manufacturing/labeling, not as a biosimilar to a reference biologic.
What’s the practical difference for patients?
Patients don’t usually choose “biosimilar vs brand” for bivalirudin the same way they might for biosimilar antibodies or factor replacement therapies. The relevant differences tend to be about the specific drug formulation and approved labeling rather than biosimilar substitution rules that apply to biologics.
Could anything be misidentified as a biosimilar?
Sometimes people use “biosimilar” loosely to mean “a cheaper copy” of a medicine. For bivalirudin, the correct framing is that it is not a biosimilar; lower-cost alternatives, if any, would be treated as non-biosimilar drug products rather than biosimilar biologics.
Sources
I don’t have any provided sources to cite for this question.